Abstract
To the Editor: Rodionov and Lentz1 summarized the homocysteine paradox. Hyperhomocysteinemia disrupts vascular structure and function in animals and predicts risk of “coronary events, stroke, venous thromboembolism, and death,” yet clinical benefit in intervention trials remains unproved. They offer several plausible explanations. Trials usually involve dietary supplementation with folate and vitamins B-6 and B-12. It also seems plausible that results would have been better if the intervention trials included copper. High homocysteine concentrations lead to increased homocysteine thiolactone,2 an …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Arteriosclerosis, Thrombosis, and Vascular Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
